The most interesting and notable lung cancer research from the 2010 ASCO (American Society of Clinical Oncology) conference.
Held in Chicago June 4-8, the annual meeting brought together 50,000 physicians, researchers, and other health care professionals from around the globe to discuss and hear the latest results in cancer research. Click the links to read the articles on the ASCO website.
Selenium conferred no protective benefit for decreasing risk of primary second tumors for patients with resected non-small cell lung cancer (NSCLC) when compared with placebo.
A new inhibitor of the ALK and c-MET/hepatocyte growth factor (HGF) receptor tyrosine kinases, crizotinib (PF-02341066), has produced an objective response rate (ORR) of 57%, disease control rate (DCR) of 87%, and progression-free survival (PFS) probability at 6 months of 72%, with an excellent safety profile, in patients with non-small cell lung cancer (NSCLC). The updated analysis was presented by Yung-Jue Bang, MD, PhD, of Seoul National University Hospital, South Korea, on behalf of his colleagues during Sunday’s Plenary Session (Abstract 3).
Treatment with a paclitaxel and carboplatin doublet resulted in better survival for elderly patients with advanced non-small cell lung cancer (NSCLC) than standard single-agent therapy.
Treatment with picoplatin, a new generation platinum compound designed to overcome platinum resistance, resulted in significant improvement in survival for selected patients with small cell lung cancer (SCLC), but overall survival did not reach statistical significance.
A strategy of first using endosonography (ES), plus surgical staging (SS) if needed for confirmation, was more sensitive for detecting lymph node metastases in non-small cell lung cancer (NSCLC) than the current strategy of proceeding directly to surgical staging, said Kurt G. Tournoy, MD, PhD, of Ghent University Hospital, Belgium, at Saturday’s Oral Abstract Session (Abstract 7000).